<div id="readability-page-1"><p>In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Aligos Therapeutics, with a price target of <span id="expert-recommendation-target">$50.00</span>.</p><h3>Claim 30% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>According to TipRanks, Trucchio is a 5-star analyst with an average return of <span>30.0%</span> and a 53.97% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Atai Beckley N.V., Definium Therapeutics, and Immunocore Holdings.</p> <p>In a report released on April 15, Piper Sandler also maintained a Buy rating on the stock with a $175.00 price target.</p></div>

ALGS

LABU

<p>H.C. Wainwright analyst Patrick Trucchio has reiterated a Buy rating on Aligos Therapeutics (ALGS) with a price target of $50.00. Trucchio, a 5-star analyst with a 30.0% average return and 53.97% success rate, focuses on the Healthcare sector. Previously, Piper Sandler also maintained a Buy rating on ALGS with a price target of $175.00.</p>

Tip Ranks

Aligos Therapeutics

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

iShares US Pharma

iShares Biotechnology ETF

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

iShares Global Healthcare

VG Health

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

AtaiBeckley

Immunocore

Piper Sandler Cos

Aligos Therapeutics (ALGS) Gets a Buy from H.C. Wainwright